Days af­ter rapid FDA ap­proval, Lil­ly and Blue­print go head-to-head again at AS­CO

Eli Lil­ly may have got­ten ahead of Blue­print with an ap­proval last week, but it looks like the Big Phar­ma and the Cam­bridge biotech will be go­ing toe-to-toe for a while.

In a pair of AS­CO ab­stracts, both Lil­ly and Blue­print once again showed off pos­i­tive da­ta from their RET-in­hibitors, set­ting up what could be a dual mar­ket for years to come. An­a­lysts have been com­par­ing the two drugs for years now, since be­fore Lil­ly ac­quired their com­pound in the $8 bil­lion Loxo buy­out. Lil­ly got an edge with an FDA ap­proval for its drug, called selper­ca­tinib or Retev­mo, last week — months ahead of the agency dead­line — but Blue­print com­plet­ed an NDA sub­mis­sion ear­li­er this year and could be not far be­hind.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER